Denmark
# |
Name |
EBITDA Margin |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
---|---|---|---|---|---|---|---|
1 |
48.79%
|
Dec. 31, 2023 | USD 81.56 | -2.90% |
|
Denmark |
|
2 |
47.56%
|
June 30, 2024 | USD 70.50 | 0.61% |
|
Denmark |
|
3 |
36.37%
|
Dec. 31, 2023 | USD 216.88 | 1.28% |
|
Denmark |
|
4 |
31.37%
|
Sept. 30, 2024 | USD 109.06 | -0.12% |
|
Denmark |
|
5 |
30.57%
|
Dec. 31, 2023 | USD 54.16 | -1.39% |
|
Denmark |
|
6 |
29.05%
|
Dec. 31, 2023 | USD 26.62 | -0.36% |
|
Denmark |
|
7 |
25.62%
|
Dec. 31, 2023 | USD 5.46 | 0.56% |
|
Denmark |
|
8 |
23.25%
|
Dec. 31, 2023 | USD 38.89 | 0.23% |
|
Denmark |
|
9 |
18.93%
|
Dec. 31, 2023 | USD 20.15 | -0.78% |
|
Denmark |
|
10 |
15.01%
|
Dec. 31, 2023 | USD 0.39 | -1.60% |
|
Denmark |
|
11 |
12.82%
|
Sept. 30, 2024 | USD 18.73 | 1.26% |
|
Denmark |
|
12 |
9.95%
|
Sept. 30, 2024 | USD 0.78 | 3.05% |
|
Denmark |
|
13 |
-13.69%
|
Dec. 31, 2023 | USD 91.43 | -1.85% |
|
Denmark |
|
14 |
-82.69%
|
Dec. 31, 2023 | USD 0.63 | -3.68% |
|
Denmark |
|
15 |
-154.16%
|
Dec. 31, 2023 | USD 131.57 | -1.84% |
|
Denmark |
|
16 |
-178.63%
|
Dec. 31, 2023 | USD 1.93 | -6.19% |
|
Denmark |
|
17 |
-186.99%
|
Dec. 31, 2023 | USD 0.20 | -2.77% |
|
Denmark |
|
18 |
-190.08%
|
Dec. 31, 2023 | USD 95.84 | 0.08% |
|
Denmark |
|
19 |
-486.97%
|
Dec. 31, 2023 | USD 0.57 | 1.47% |
|
Denmark |
|
20 |
-1,388.16%
|
Dec. 31, 2023 | USD 2.17 | 5.88% |
|
Denmark |
|
21 |
-10,378.96%
|
Dec. 31, 2023 | USD 3.98 | 0.01% |
|
Denmark |
The Health Care company in Denmark with the highest EBITDA Margin is Novo Nordisk A/S (Copenhagen Stock Exchange: NOVO-B.CO) at 48.79%.
The Health Care company in Denmark with the lowest EBITDA Margin is FluoGuide A/S (Stockholm Stock Exchange: FLUO.ST) at -10,378.96%.
The top 10 Health Care companies in Denmark by EBITDA Margin are Novo Nordisk A/S, ChemoMetec A/S, Genmab A/S, Coloplast A/S, Novozymes A/S, Bavarian Nordic A/S, H. Lundbeck A/S, Demant A/S, ALK-Abelló A/S and Danish Aerospace Company A/S.
The bottom 10 Health Care companies in Denmark by EBITDA Margin are FluoGuide A/S, ExpreS2ion Biotech Holding AB (publ), Saniona AB (publ), Zealand Pharma A/S, BioPorto A/S, ViroGates A/S, Ascendis Pharma A/S, BactiQuant A/S, Gubra A/S and Scandinavian Medical Solutions A/S.